Immunotherapy Resistance in Pancreatic Cancer

Video

This video examines the role of immunotherapy in pancreatic cancer, highlighting the resistance to novel treatments in this setting and trials attempting to confront this problem.

In this video, Gregory L. Beatty, MD, PhD, of the University of Pennsylvania, discusses the role of immunotherapy in pancreatic cancer, highlighting the resistance to novel treatments in this setting, and how trials are being designed to confront this problem.

Beatty gave a presentation on this subject at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.
Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.
It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.
Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
Related Content
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.

Adapting a Computation Linguistics Model to Surveil for Pancreatic Cancer

Russell C. Langan, MD
November 24th 2024
Article

An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

The incorporation of palliative care specific to mental health services and therapy remains underutilized in the care of patients with pancreatic cancer.

Palliative Care May Improve Mental Health in Pancreatic Cancer Diagnoses

Gina Mauro
November 19th 2024
Article

The incorporation of palliative care specific to mental health services and therapy remains underutilized in the care of patients with pancreatic cancer.

Experts from Vanderbilt Medical Center review mechanisms, supporting data, and patient cases associated with the use of IORT in pancreatic cancer.

Advancing Pancreatic Cancer Care Through Intraoperative Radiation Therapy

Kamran Idrees, MD, MSCI, MMHC, FACS ;Natalie A. Lockney, MD;Milad Baradaran, PhD, DABR
August 5th 2024
Podcast

Experts from Vanderbilt Medical Center review mechanisms, supporting data, and patient cases associated with the use of IORT in pancreatic cancer.

Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?

Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?

Natasha Bahri, MD, MS;Christiana Crook, MS;Daneng Li, MD
November 12th 2024
Article

Given that well-differentiated grade 3 NETs are relatively new, standard-of-care treatment options are undefined.

The 18-month overall survival rate with the mitazalimab combination in OPTIMIZE-1 exceeds a historical rate achieved with FOLFIRINOX alone.

Mitazalimab Combo Yields Meaningful Survival Benefit in Metastatic PDAC

Russ Conroy
November 7th 2024
Article

The 18-month overall survival rate with the mitazalimab combination in OPTIMIZE-1 exceeds a historical rate achieved with FOLFIRINOX alone.